Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

• প্রধান লেখক: Rosanna Ruggiero (লেখক), Federica Fraenza (লেখক), Cristina Scavone (লেখক), Gabriella di Mauro (লেখক), Raffaele Piscitelli (লেখক), Annamaria Mascolo (লেখক), Carmen Ferrajolo (লেখক), Concetta Rafaniello (লেখক), Liberata Sportiello (লেখক), Francesco Rossi (লেখক), Annalisa Capuano (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Frontiers Media S.A., 2020-06-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

BackgroundThe introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ipilimumab. Despite their proven clinical efficacy,...